Nimbus Apollo, Inc.

2022年12月13日，武田与Nimbus Therapeutics围绕TYK2抑制剂达成了一笔首付款40亿美元，总金额60亿美元的合作。这可能是今年医药领域第5起超过50亿美元的「非并购」交易。之所以说可能，是因为双方公布的信息略有出入。武田方面的说法是：从Nimubs手里买了一款产TYK2抑制剂（代号：NDI-034858，以下用其在武田的新代号：TAK-279）。Nimbus那边的说法是：武田收购了Nimbus Therapeutics 的全资子公司Nimbus Lakshmi及TAK-279，并获得了该产品和其他TYK2抑制剂未来的开发和商业化权利。区别在于，除了TAK-279，武田是否还获得了其他资产？仔细研究了一下，应该没有。所以，我们可以将其理解为围绕着单产品的一笔巨额交易。今年里另外4起非并购巨额交易分别是：罗氏与Poseida围绕通用型CAR-T的超60亿美元合作；赛诺菲与Exscientia围绕AI技术平台的53亿美元合作；赛诺菲与IGM围绕抗体技术平台的超60亿美元合作；以及Summit斥资50亿美元引进康方生物的AK112。本次武田交易的亮点，除了历史级别的首付款和总交易额之外，还在于这个Nimbus是个使用了AI制药概念的公司，站在他背后的是AI制药界的顶流：薛定谔（Schrodinger）。1成熟的盈利模式Nimbus成立于2009年，薛定谔是其创始合作伙伴，也有说是薛定谔公司参与创立的Nimbus，总之二者有着密切的关系。据Nimbus官网介绍，其核心方法是构架一个“基于结构”的新药发现引擎来选择靶点、设计新分子。改引擎的核心是将计算化学（computational chemistry）与其他技术结合，更有效地利用高分辨率蛋白质结构数据来研究药物靶点并调节其功能活性。而计算化学的技术就是来自薛定谔，该技术可以从物理学的角度对靶点活性和变构位点进行分析，并依照所需的结合模式、功能活性和选择性设计小分子调节剂。早在2016年，Nimbus就与吉利德达成了一笔总金额12亿美元的交易。吉利德获得了其管线内靶向乙酰辅酶A 羧化酶（ACC）的NASH候选药物（吉利德方代号：GS-0976），首付款高达4亿美元。薛定谔公司从这笔交易中获得4600万元美元的首付款和4600万美元里程碑付款。与武田的交易类似，GS-0976也是挂在了Nimbus的全资子公司Nimbus Apollo名下，吉利德连公司带产品一起打包带走，以至于后来消息几经转手后，变成了Nimbus Therapeutics 被吉利德以12亿美元收购。通过两笔交易我们不难看出，Nimbus的商业模式就是靠卖候选药物赚钱，甚至都没有自己商业化的欲望，为了方便客户，把每一款药物的归属权及专利都放在一个单独的子公司名下，卖的时候就打包一起卖掉。既发挥了AI辅助药物研发的特点，又规避了biotech的商业化难题。尽管成立到现在只做成了两单生意，总金额却有72亿美元，且首付款高达44亿美元，足以让大部分biotech汗颜。2「刁钻」的研发方向有薛定谔站台，又与吉利德、新基和基因泰克等知名企业有过成果交易，Nimbus丝毫没有感受到“寒冬”的凌冽，成立至今，获得的投资总金额超过了10亿美元，投资者包含了礼来基金、Atlas Venture、Access Biotechnology等知名机构，还有比尔·盖茨。不差钱的影响就是，看不上没意思的东西，也从不跟风，只专注于在「刁钻」的领域做有潜力的产品，例如本次成交的TYK2抑制剂。TYK2是JAK的近亲，与JAK抑制剂一样在自身免疫性疾病，如银屑病、类风湿性关节炎、炎性肠炎、红斑狼疮等领域有极大潜力。JAK抑制剂的竞争已经极为激烈，艾伯维将乌帕替尼视为修美乐的“继任者”，辉瑞、礼来也都有布局。但无论是哪个JAK抑制剂，都严重的安全风险，因为JAK掌管的信号通路太多了，管的多，就容易有副作用，会诱发血栓、严重感染、心血管疾病等问题，上述JAK抑制剂无一例外被FDA“授予”了黑框警告。TYK2就要“专一”的多，不仅安全性更好，而且是口服的。今年9月，FDA批准了BMS的TYK2抑制剂Sotyktu上市，预计巅峰销售额会达到40亿美元。Nimbus的TYK2抑制剂研发进度在全球前列，两周前刚刚公布了2b期临床试验结果，达到了主要疗效终点，但是没有公布具体数值，只说显著优于安慰剂。但是从武田的反应来看，效果应该是非常好。据说两家公司在去年就已经在围绕该产品进行谈判，武田会在结果出炉后迅速以如此高的价格买入，显然是十分看好。卖掉TYK2之后，Nimbus的管线中最靠前的是HPK1抑制剂，从进展来看有First-in-class的潜力。另外还有AMPKb2、CTPS1、Cbl-b、和WRN四个项目，这些靶点平时都很少看见，基本都是难以成药的老靶点，不是配体少就是结构奇怪。也就Nimbus这样有钱、有闲、有新技术的公司会去试着做。3结语Nimbus是未上市公司，看不出交易对其的影响。但昨天的额交易达成后，薛定谔公司股价立刻上涨了20.61%，一定程度上反应了资本市场的态度。 来源：雪球对整个AI制药行业来说，这也算是个里程碑事件。药物研发流程太长，靠AI很难全部走通，那是做“点”还是做“面”？做靶点筛选还是做晶型筛选？都是问题。真正靠AI主导药物设计，目前还非常困难，在肉眼可见的未来，AI还难以在某个制药环节替代人力，首先要做的就是数据的标准化和通量化。在一个病理分析还要靠医生用肉眼做判断的时代，AI制药还有很长的路要走。AI的定位更适合做一个辅助，AI制药公司最好还是有专业的制药团队，不仅可以相辅相成，还能用实验室的数据反哺AI进行深度学习。面对AI，不依赖、不恐惧，客观、理智地将其作为一项新技术看待，这种态度才刚好。参考资料：武田官网Nimbus Therapeutics官网比尔·盖茨、谷歌、药明康德、启明创投投资的Schrodinger今美股上市，首日上涨68.47%！AI制药公司Nimbus，缘何受到比尔•盖茨青睐？原创 | Nimbus大阅兵其他公开资料4这是一个广告虽然Nimbus不跟风，但更多的企业还是会追逐火热的赛道，ADC就是其中之一，国内已有几十家药企布局ADC领域。据Evaluate Pharma和BCG的预测，全球ADC市场预计2024年将达到129亿美元，2018至2024年的年复合增长率约为35%。2026年更是有望达到160多亿美元。不断加剧的内外竞争、内卷现状也催促行业和我们思考：如何应对这些越来越大的挑战？如何利用火热的AI研发更优质、更有竞争力的ADC新药？2022年12月15日（本周四）19:30-21:00，药时代邀请映恩生物首席科学官邱杨博士、晶泰科技技术总监张臣博士莅临直播间，分享他们的真知灼见及各自公司的喜人成果。欢迎广大朋友前来观看。点击这里，进入直播间！

With Phase 3 Study in Psoriasis Expected to Start in 2023, NDI-034858 Has the Potential to Demonstrate Best-in-class Efficacy and Safety in Psoriasis As Well As Multiple Other Immune-Mediated Diseases, Including Inflammatory Bowel Disease, Psoriatic Arthritis and Systemic Lupus Erythematosus Acquisition Strengthens Takeda’s Growing Late-stage Pipeline, in Alignment With the Company’s Therapeutic Area Strategy and Expertise in Immune-Mediated Diseases OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. When the transaction is complete, NDI-034858 will be known as TAK-279. “Adding this TYK2 inhibitor to our late-stage pipeline gives Takeda an exciting program that has the potential to significantly expand our portfolio and patient impact, while enhancing our growth strategy beyond ENTYVIO®” said Christophe Weber, president and chief executive officer of Takeda. “We are confident we can execute a broad development program and deliver a best-in-class therapy for these patients, given Takeda’s strong background in immune-mediated diseases, including inflammatory bowel disease (IBD).” Nimbus recently disclosed positive topline results from a Phase 2b study evaluating NDI-034858 in patients with moderate-to-severe plaque psoriasis. Takeda intends to present results from this Phase 2b study early in 2023. NDI-034858 is anticipated to enter Phase 3 in psoriasis in 2023. It is in an ongoing Phase 2b study in active psoriatic arthritis, and Takeda plans to investigate it for the treatment of IBD and other autoimmune diseases. “This program further expands Takeda’s GI clinical programs and therapeutic focus. After having seen the NDI-034858 Phase 2b data, particularly the PASI scores, we are excited by the differentiation of this molecule within the TYK2 class, and we believe in its broad potential for people with autoimmune diseases,” said Andy Plump, M.D., Ph.D., president of Research & Development at Takeda. “By virtue of its unique allosteric mechanism of action, NDI-034858 is both a potent and highly selective TYK2 inhibitor with exceptional clinical activity, a strong tolerability pro wide therapeutic margins. NDI-034858 is a potentially best-in-class TYK2 inhibitor across a wide range of immune mediated conditions.” “Since the acquisition of Shire in 2019, we have made excellent progress in reducing our debt ratio towards ‘low-twos’ net debt to adjusted EBITDA and we are on course to achieve this target one year ahead of plan. This acquisition is an opportunity to invest in the company’s mid-to-long term growth. Even after closing the deal, we expect to end this fiscal year with a debt ratio in the ‘low-to-mid-twos,’ and with a weighted average interest fixed rate of approximately 2%,” said Costa Saroukos, chief financial officer of Takeda. “Takeda’s solid financial pro robust cash flow outlook positions the company well to invest in growth drivers and focus on shareholder returns, while maintaining solid investment grade credit ratings.” Under the terms of the agreement, Takeda will pay Nimbus $4B upfront, and two milestone payments of $1B each upon achieving annual net sales of $4B and $5B. The upfront payment will be primarily funded by cash on hand. The transaction is expected to be finalized before the end of FY2022. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. Evercore Group LLC is acting as exclusive financial advisor to Takeda and Cleary Gottlieb Steen & Hamilton LLP is acting as its legal advisor. Takeda management will be hosting a virtual meeting for investors and analysts to discuss this announcement from 5:30 - 6:15 p.m. EST on Tuesday, December 13 / 7:30 – 8:15 a.m JST on Wednesday, December 14. Please click here to participate. About NDI-034858 NDI-034858 is an allosteric TYK2 inhibitor developed by Nimbus Therapeutics that is being evaluated for the treatment of multiple autoimmune diseases. In preclinical studies, NDI-034858 has demonstrated exceptional functional selectivity and wide therapeutic margins. In Phase 1 studies, NDI-034858 showed a good tolerability profile, a dose-dependent trend in exploratory clinical activity and a pharmacokinetic pro for once-daily solid oral dosing. Positive topline results were reported from a Phase 2b clinical trial evaluating NDI-034858 in patients with moderate-to-severe plaque psoriasis. NDI-034858 is in an ongoing Phase 2b trial in active psoriatic arthritis (NCT05153148). About Takeda Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit . About Nimbus Therapeutics Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. Nimbus combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus’ pipeline includes clinical-stage programs targeting TYK2 and HPK1 (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, inflammatory and autoimmune disorders and metabolic diseases. Nimbus is headquartered in Boston, MA. To learn more about Nimbus, please visit . Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we,” “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets,” “plans,” “believes,” “hopes,” “continues,” “expects,” “aims,” “intends,” “ensures,” “will,” “may,” “should,” “would,” “could” “anticipates,” “estimates,” “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. Medical information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. ### News Release Takeda to Acquire 100% Ownership of Nimbus Therapeutics’ TYK2 Program Subsidiary OSAKA, Japan and CAMBRIDGE, Massachusetts, December 13, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced that its Board of Directors has decided and entered into an agreement to acquire all shares of Nimbus Lakshmi, Inc. (“Lakshmi”), a wholly-owned subsidiary of Nimbus Therapeutics, LLC (“Nimbus”). Headquartered in Boston, MA, Nimbus is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The Lakshmi program includes the lead molecule, NDI-034858, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases. NDI-034858 has the potential to demonstrate best-in-class efficacy and safety in multiple immune-mediated diseases including psoriasis, inflammatory bowel disease, psoriatic arthritis, and systemic lupus erythematosus. Under the terms of the agreement, Takeda will pay Nimbus $4B upfront, and two milestone payments of $1B each upon achieving annual net sales of $4B and $5B. The upfront payment will be primarily funded by cash on hand. The transaction is expected to be finalized before the end of FY2022. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. 1. Rationale for the share acquisition Please refer to the attachment “Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics”, for the rationale behind acquiring the TYK2 program held by Lakshmi through a share acquisition. 2. Overview of Lakshmi, a subsidiary which will be acquired by Takeda (1) Name Nimbus Lakshmi, Inc. (2) Address 22 Boston Wharf Road, Floor 9 Boston, MA 02210 USA (3) Representative Jeb Keiper, Chief Executive Officer (4) Scope of business Holding intellectual properties (5) Date of establishment April 12, 2010 (6) Major shareholders and ownership ratio Nimbus Therapeutics, LLC　100% (7) Relationships with Takeda Capital Relationship There is no capital relationship between Lakshmi and Takeda. Personnel Relationship There is no personnel relationship between Lakshmi and Takeda. Business Relationship There is no business relationship between Lakshmi and Takeda. 3. Overview of Nimbus, a counterparty to the share acquisition (1) Name Nimbus Therapeutics, LLC (2) Address 22 Boston Wharf Road, Floor 9 Boston, MA 02210 USA (3) Representative Jeb Keiper, Chief Executive Officer (4) Scope of business Research and development of pharmaceutical drugs (5) Date of establishment March 26, 2010 (6) Relationships with Takeda Capital Relationship There is no capital relationship between Nimbus and Takeda. Personnel Relationship There is no personnel relationship between Nimbus and Takeda. Business Relationship There is no business relationship between Nimbus and Takeda. Related party relationship There is no related party relationship between Nimbus and Takeda. 4. Number of shares to be acquired, acquisition price, and number of shares held by Takeda before and after acquisition (1) Number of shares held before acquisition 0 shares (Percentage of voting rights: 0%) (2) Number of shares to be acquired 1,000 shares of Series A Common Stock and 1 share of Series B Common Stock (3) Acquisition price* 4 billion USD (actual price will be determined after adjustment for items including closing indebtedness and closing account payable of Lakshmi) (4) Number of shares held after acquisition 1,000 shares of Series A Common Stock and 1 share of Series B Common Stock (Percentage of voting rights: 100%) * Additionally, there will be two milestone payments of $1 billion each upon achieving annual net sales of $4 billion and $5 billion for NDI-034858. 5. Schedule (1) Date of decision on the share acquisition by the Director delegated by the Board of Directors December 13, 2022 (2) Date of conclusion of agreement on the share acquisition December 13, 2022 (3) Date of the share acquisition By March 31, 2023 (planned) 6. Future outlook Takeda will continue to assess the impact of the share acquisition and other factors and will update its forecast for the fiscal year ending March 31, 2023 at the appropriate timing, as necessary. (Reference) Forecasts for the full year consolidated financials for the fiscal year 2022 (announced on October 27, 2022) and the full year consolidated financial results for the fiscal year 2021 (millions JPY) Revenue Operating profit Profit before income taxes Net profit attributable to owners of the Company Basic earnings per share FY2022 Forecast 3,930,000 530,000 426,000 307,000 197.83 JPY FY2021 Results 3,569,006 460,844 302,571 230,059 147.14 JPY About Takeda Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit . Contacts Investor Relations Christopher O’Reilly christopher.oreilly@takeda.com +81 (0) 3-3278-2543 Media Relations U.S. and International Catherine Wilson Catherine.Wilson@takeda.com +1 (440) 488-6242 Japan Jun Saito Jun.Saito@takeda.com +81 (0) 3-3278-2325 Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we,” “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets,” “plans,” “believes,” “hopes,” “continues,” “expects,” “aims,” “intends,” “ensures,” “will,” “may,” “should,” “would,” “could,” “anticipates,” “estimates,” “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); the extent to which our internal energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at . Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this report may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. Medical information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

- Nimbus to receive $4 billion in upfront cash, and up to $2 billion in commercial milestone payments - - NDI-034858 has potential best-in-class pro new therapeutic class of selective allosteric TYK2 inhibitors for immune-mediated diseases - BOSTON--(BUSINESS WIRE)-- Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced that it has signed a definitive agreement under which Takeda (TSE:4502/NYSE:TAK) will acquire Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858 is an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. “Nimbus’ allosteric TYK2 inhibitor has the potential to be a best-in-class medicine in multiple disease areas, and we are confident that Takeda’s commitment and capabilities will enable NDI-034858 to reach its full value to patients,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “The proposed acquisition highlights Nimbus’ ability to discover and develop high-value investigational medicines leveraging our computational structure-based drug design and development engine. We will continue to advance other exciting target programs in our R&D pipeline — including our selective HPK1 inhibitor, currently in a Phase 1/2 study in patients with solid tumors — as we have done since our founding in 2009.” Under the terms of the agreement, Takeda will pay Nimbus Therapeutics $4 billion upfront, and sales-based milestone payments up to $2 billion. The transaction is expected to be finalized in the first half of 2023. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. Nimbus Therapeutics will retain ownership of its other research and development subsidiaries. Takeda will be solely responsible for future development and commercialization of NDI-034858 and other TYK2 inhibitors. J.P. Morgan Securities LLC is acting as exclusive financial advisor to Nimbus Therapeutics and Goodwin Procter LLP is serving as its legal advisor. About NDI-034858 NDI-034858 is an allosteric TYK2 inhibitor discovered and developed by Nimbus Therapeutics that is being evaluated for the treatment of multiple autoimmune diseases. In preclinical studies, NDI-034858 has demonstrated exceptional functional selectivity and wide therapeutic margins. In Phase 1 studies, NDI-034858 showed a good tolerability profile, a dose-dependent trend in exploratory clinical activity and a pharmacokinetic pro for once-daily solid oral dosing. Results from Nimbus’ Phase 2b clinical trial in patients with moderate-to-severe plaque psoriasis demonstrated a significantly greater proportion of patients in the study achieving the primary endpoint of PASI-75 (a 75% improvement in skin lesions as measured by the Psoriasis Area and Severity Index) compared to placebo after twelve weeks of treatment. Data from this trial will be presented at an upcoming medical conference. In addition to psoriasis, NDI-034858 is in an ongoing Phase 2b trial in active psoriatic arthritis (NCT05153148). About Nimbus Therapeutics Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. Nimbus combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus’ pipeline includes clinical-stage programs targeting TYK2 and HPK1 (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, inflammatory and autoimmune conditions and metabolic diseases. Nimbus is headquartered in Boston, MA. To learn more about Nimbus, please visit .